Program
IPG-7236
Also written as “IPG7236”, “IPG7236- Single ascending dose” and “IPG7236- Multiple ascending dose”.
Its studies are mostly in Dermatitis, Atopic, led by Nanjing Immunophage Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing Immunophage Biotech | 31 open or running | phase 2since Nov 21, 2021 | Nov 21, 2021 | Dec 30, 2028phase 2 · NCT07508761 |
Also a collaborator on its studies: novotech-australia-pty-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 21, 2021First study: phase 2 study in Safety IssuesFirst studyNCT05142592 · 34 enrolled · United States, China
- Mar 17, 2022Phase 1 study in Dermatitis, AtopicNCT05288543 · 63 enrolled · Australia
- Mar 23, 2026Phase 2 study in Advanced Solid TumorNCT07508761 · 52 planned · China
Ahead
- Dec 30, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT07508761
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07508761Advanced Solid Tumor · China | 2 | Recruiting | Dec 30, 2028 | 52 |
| NCT05288543Dermatitis, Atopic · Australia | 1 | Terminated | Mar 31, 2023 | 63 |
| NCT05142592Safety Issues · United States, China | 2 | Completed | Feb 8, 2026 | 34 |
How it is read
Names in the registry
- “IPG7236”, 2 entries
- “IPG7236- Single ascending dose”, 1 entry
- “IPG7236- Multiple ascending dose”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.